

CLAIM AMENDMENTS

Claims 1-98 (Canceled)

99. **(Currently Amended)** A composition comprising synergistic effective amounts of an anti-diabetic agent other than insulin, a bioavailable source of chromium, and a bioavailable source of vanadium, wherein said anti-diabetic agent is a sulfonylurea, and wherein components of said composition synergistically reduce the HbA1c levels of a patient by at least about 10% after treatment for a period of at least about thirty days with said composition as compared to treatment with said anti-diabetic agent alone.

Claims 100-102 (Canceled)

103. **(Previously Presented)** The composition according to claim 99, wherein said sulfonylurea is one of the following: acetohexamide, chlorpropamide, tolazimide, tolbutamide, glycazide, glipizide, glyburide, or glimeperide.

Claims 104-114 (Canceled)

115. **(Currently Amended)** A method for improving glucose metabolism, comprising treating a patient for at least about a thirty day period by administering a pharmaceutical composition comprising synergistic effective amounts of an anti-diabetic agent other than insulin, a bioavailable source of chromium, and a bioavailable source of vanadium, wherein said anti-diabetic agent is a sulfonylurea, and wherein said components of said composition synergistically reduce the HbA1c level of said patient by at least about 10% after such treatment as compared to treatment with said anti-diabetic agent alone.

Claims 116-133 (Canceled)

134. **(New)** The composition of claim 99, wherein said reduction in said Hb1Ac level is at least about 50%.

135. **(New)** The composition of claim 99, wherein said bioavailable source of chromium comprises one or more of chromium picolinate or chromium polynicotinate.

136. (New) A composition according to claim 135, wherein the bioavailable source of chromium is chromium picolinate and wherein the amount of chromium picolinate is from about 30 µg up to about 1000 µg, per dose.

137. (New) A composition according to claim 135, wherein the bioavailable source of chromium is chromium polynicotinate and wherein the amount of chromium polynicotinate is from about 30 µg up to about 5000 µg, per dose.

138. (New) The composition of claim 99, wherein said bioavailable source of chromium comprises no less than about 200 micrograms of elemental chromium.

139. (New) The composition of claim 99, wherein said bioavailable source of chromium comprises no less than about 100 micrograms of elemental chromium.

140. (New) The composition of claim 99, wherein said bioavailable source of chromium comprises no less than about 5 micrograms of elemental chromium.

141. (New) The composition of claim 99, wherein said bioavailable source of vanadium is vanadyl sulfate.

142. (New) The composition of claim 141, wherein the amount of vanadyl sulfate is in the range of about 20 mg up to about 100 mg, per dose.

143. (New) The composition of claim 99, wherein said bioavailable source of vanadium comprises more than about 10 mg elemental vanadium.

144. (New) The composition of claim 99, wherein said amount of said bioavailable source of vanadium comprises no less than 5 mg of elemental vanadium.

145. (New) The composition according to claim 99, wherein said sulfonylurea is one of the following: acetohexamide, chlorpropamide, tolazimide, or tolbutamide.

146. (New) The composition according to claim 99, wherein said sulfonylurea is one of the following: glycazide, glipizide, glyburide, or glimeperide.

147. (New) The composition according to claim 99, wherein said sulfonylurea is glyburide.

148. (New) The composition according to claim 99, wherein said sulfonylurea is glipizide.

149. (New) The composition according to claim 99, wherein said sulfonylurea is glimeperide.

150. **(New)** The composition according to claim 135, wherein said sulfonylurea is one of the following: acetohexamide, chlorpropamide, tolazimide, tolbutamide, glycazide, glipizide, glyburide, or glimeperide.

151. **(New)** The composition according to claim 141, wherein said sulfonylurea is one of the following: acetohexamide, chlorpropamide, tolazimide, tolbutamide, glycazide, glipizide, glyburide, or glimeperide.

152. **(New)** The composition according to claim 135, wherein said sulfonylurea is one of the following: acetohexamide, chlorpropamide, tolazimide, or tolbutamide.

153. **(New)** The composition according to claim 135, wherein said sulfonylurea is one of the following: glycazide, glipizide, glyburide, or glimeperide.

154. **(New)** The composition according to claim 141, wherein said sulfonylurea is one of the following: acetohexamide, chlorpropamide, tolazimide, or tolbutamide.

155. **(New)** The composition according to claim 141, wherein said sulfonylurea is one of the following: glycazide, glipizide, glyburide, or glimeperide.

156. **(New)** The method of claim 115, wherein said bioavailable source of chromium comprises no less than about 200 micrograms elemental chromium when said composition is administered on a daily basis.

157. **(New)** The method of claim 115, wherein said bioavailable source of chromium comprises no less than about 5 micrograms of elemental chromium when said composition is administered on a daily basis.

158. **(New)** The composition of claim 115, wherein said bioavailable source of chromium comprises one or more of chromium picolinate or chromium polynicotinate.

159. **(New)** The method of claim 115, wherein said bioavailable source of vanadium comprises at least about 10 mg elemental vanadium when said composition is administered on a daily basis.

160. **(New)** The method of claim 115, wherein said bioavailable source of vanadium is vanadyl sulfate.

161. (New) The method of claim 115, wherein said amount of said bioavailable source of vanadium comprises no less than 5 mg of elemental vanadium when said composition is administered on a daily basis.

162. (New) The composition according to claim 115, wherein said sulfonylurea is one of the following: glycazide, glipizide, glyburide, or glimeperide.

163. (New) The composition according to claim 115, wherein said sulfonylurea is one of the following: acetohexamide, chlorpropamide, tolazimide, or tolbutamide.

164. (New) The composition according to claim 115, wherein said sulfonylurea is glyburide.

165. (New) The composition according to claim 115, wherein said sulfonylurea is glipizide.

166. (New) The method of claim 115, wherein said pharmaceutical composition further comprises a physiologically acceptable carrier.

167. (New) The method of claim 115, wherein said method further comprises monitoring said subject's HbA1c levels.

168. (New) The method of claim 115, wherein said reduction in said Hb1Ac level is at least about 50%.